Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001193353 | SCV001362113 | likely pathogenic | O'Donnell-Luria-Rodan syndrome | 2019-08-14 | criteria provided, single submitter | clinical testing | Variant summary: KMT2E c.3917dupT (p.Pro1307ThrfsX6) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations upstream- and downstream of this position have been reported in patients affected with O'Donnell-Luria-Rodan Syndrome (see PMID: 31079897, and in ClinVar) or related phenotypes (e.g. autism spectrum disorder, mental retardation; in HGMD and ClinVar). The variant was absent in 251178 control chromosomes (gnomAD). In addition, manual curation of all putative protein-truncating variants in the gnomAD database confirmed that those variants that are expected to result in true protein truncation are very rare in the KMT2E gene (PMID: 31079897). To our knowledge, no occurrence of c.3917dupT in individuals affected with O'Donnell-Luria-Rodan Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |